TABLE 1.
Baseline mechanical hypersensitivity prior to the injection of either milnacipran or saline (vehicle) in both phases of the MIA model
Data presented as the median number of hind-limb withdrawals from 10 applications to each paw of 1-, 6-, and 8-g vF filaments. n = 8 in each group, in both phases of the model.
| vF | +Milnacipran |
+Saline |
|||
|---|---|---|---|---|---|
| IL | CL | IL | CL | ||
| g | median (interquartile range) | ||||
| Early phase | 1 | 1.0 (0-1) | 0 (0-1) | 0.5 (0-1) | 0 (0-1) |
| 6 | 5.5 (3-6) | 0.0 (0-1) | 4.5 (4-7) | 0 (0-1) | |
| 8 | 8.0 (7-9) | 1.0 (0-1) | 8.0 (5-9) | 1 (0-2) | |
| Late phase | 1 | 0.0 (0-2) | 0.0 (0-1) | 1.0 (0-1) | 0.0 (0-1) |
| 6 | 3.5 (1-5) | 0.0 (0-0) | 4.0 (1-6) | 0.5 (0-1) | |
| 8 | 7.5 (4-8) | 0.0 (0-1) | 6.0 (5-9) | 1.0 (0-2) | |
CL, contralateral; MIA, monosodium iodoacetate; IL, ipsilateral; vF, von Frey.